Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 31;12(1):e054688.
doi: 10.1136/bmjopen-2021-054688.

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

Niels Adriaenssens  1 , Beatrice Scholtes  2 , Robin Bruyndonckx  3   4 , Jan Y Verbakel  5   6 , An De Sutter  7 , Stefan Heytens  7 , Ann Van den Bruel  5 , Isabelle Desombere  8 , Pierre Van Damme  9 , Herman Goossens  4 , Laëtitia Buret  2 , Els Duysburgh  10 , Samuel Coenen  11   4
Affiliations

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

Niels Adriaenssens et al. BMJ Open. .

Abstract

Introduction: National SARS-CoV-2 seroprevalence data provide essential information about population exposure to the virus and help predict the future course of the epidemic. Early cohort studies have suggested declines in levels of antibodies in individuals associated with, for example, illness severity, age and comorbidities. This protocol focuses on the seroprevalence among primary healthcare providers (PHCPs) in Belgium. PHCPs manage the vast majority of (COVID-19) patients and therefore play an essential role in the efficient organisation of healthcare. Currently, evidence is lacking on (1) how many PHCPs get infected with SARS-CoV-2 in Belgium, (2) the rate at which this happens, (3) their clinical spectrum, (4) their risk factors, (5) the effectiveness of the measures to prevent infection and (6) the accuracy of the serology-based point-of-care test (POCT) in a primary care setting.

Methods and analysis: This study will be set up as a prospective cohort study. General practitioners (GPs) and other PHCPs (working in a GP practice) will be recruited via professional networks and professional media outlets to register online to participate. Registered GPs and other PHCPs will be asked at each testing point (n=9) to perform a capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2 and complete an online questionnaire. The primary outcomes are the prevalence and incidence of antibodies against SARS-CoV-2 in PHCPs during a 12-month follow-up period. Secondary outcomes include the longevity of antibodies against SARS-CoV-2.

Ethics and dissemination: Ethical approval has been granted by the ethics committee of the University Hospital of Antwerp/University of Antwerp (Belgian registration number: 3002020000237). Alongside journal publications, dissemination activities include the publication of monthly reports to be shared with the participants and the general population through the publicly available website of the Belgian health authorities (Sciensano).

Trial registration number: NCT04779424.

Keywords: COVID-19; general medicine (see internal medicine); primary care; public health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Participant flow. PHCP, primary healthcare provider; POCT, point-of-care test.
See this image and copyright information in PMC

References

    1. WHO coronavirus (COVID-19) Dashboard. Available: https://covid19.who.int [Accessed 17 May 2021].
    1. Alter G, Seder R. The power of antibody-based surveillance. N Engl J Med 2020;383:1782–4. 10.1056/NEJMe2028079 - DOI - PMC - PubMed
    1. Koopmans M, Haagmans B. Assessing the extent of SARS-CoV-2 circulation through serological studies. Nat Med 2020;26:1171–2. 10.1038/s41591-020-1018-x - DOI - PubMed
    1. Gudbjartsson DF, Norddahl GL, Melsted P, et al. . Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724–34. 10.1056/NEJMoa2026116 - DOI - PMC - PubMed
    1. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. . Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:535–44. 10.1016/S0140-6736(20)31483-5 - DOI - PMC - PubMed

Publication types

Associated data